TF 2-targeted cancer therapy

Drug Profile

TF 2-targeted cancer therapy

Alternative Names: Dual modality imaging - Immunomedics; TF2

Latest Information Update: 04 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IBC Pharmaceuticals; Immunomedics
  • Developer Immunomedics; Nantes University Hospital
  • Class Antibody diagnostics; Antineoplastics; Bispecific antibodies; Monoclonal antibodies; Radiopharmaceutical diagnostics
  • Mechanism of Action CEACAM5 protein inhibitors; Ionising radiation emitters; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer
  • Phase I/II Breast cancer; Non-small cell lung cancer; Small cell lung cancer; Thyroid cancer

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 01 Dec 2016 Immunomedics completes a phase I/II trial in Thyroid cancer in France (IV) (NCT01730638)
  • 09 Feb 2016 TF 2 is still in phase I/II trials for Breast cancer, Small cell lung cancer, Non-small cell lung cancer and Thyroid cancer in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top